Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine.
Respiratory syncytial virus is an important human pathogen causing serious lower respiratory tract infections of children and elderly people. Previous studies on the development of experimental subunit vaccines either expressed by recombinant DNA technology or prepared from purified viral proteins absorbed on adjuvant (ISCOMs) have shown promise. The present work reports on the effectiveness of an experimental ISCOMs vaccine in initiating humoral and cell-mediated immune responses and in providing overall protection upon live virus challenge in Balb/c mice; results indicate that vaccination by the intramuscular route is more effective, even if vaccination by the intranasal route also significantly reduced virus shedding.
Trudel
M
M
Centre de recherche en virologie, Institut Armand-Frappier, Université du Québec, Laval, Canada.
Nadon
F
F
Séguin
C
C
Brault
S
S
Lusignan
Y
Y
Lemieux
S
S
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005260:Female; D007376:Interleukin-2 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology / Q000302:isolation & purification; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification
D000914:Antibodies, Viral; D007376:Interleukin-2; D014614:Vaccines, Synthetic; D014765:Viral Vaccines